Skip to main
ABSI

Absci Corp (ABSI) Stock Forecast & Price Target

Absci Corp (ABSI) Analyst Ratings

Based on 6 analyst ratings
Strong Buy
Strong Buy 83%
Buy 17%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Absci is a leading AI-powered synthetic biology company that has a clear competitive advantage in the drug discovery process through its integrated platform. With its lead product candidate, ABS-201, showing promising results in its Phase 1 trial, there is a high likelihood of successful efficacy readouts in the near future. Additionally, the company's solid financial standing, with $201 million in cash as of 2Q:26, and partnerships with major pharmaceutical companies like Eli Lilly, further supports a positive outlook for the company.

Bears say

Absci is a biotechnology company utilizing artificial intelligence and synthetic biology to expand the therapeutic potential of proteins. Despite promising data from peer companies in the same field, Absci's lead product candidate, ABS-201, is still in early stages of development and may face hurdles in gaining regulatory approval. Additionally, Absci's pipeline and platform are also in early stages, with no guarantee of success in the clinic, leading to a negative outlook for the company's stock.

Absci Corp (ABSI) has been analyzed by 6 analysts, with a consensus rating of Strong Buy. 83% of analysts recommend a Strong Buy, 17% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Absci Corp and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Absci Corp (ABSI) Forecast

Analysts have given Absci Corp (ABSI) a Strong Buy based on their latest research and market trends.

According to 6 analysts, Absci Corp (ABSI) has a Strong Buy consensus rating as of Aug 30, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $14, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $14, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Absci Corp (ABSI)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.